195 related articles for article (PubMed ID: 8822535)
1. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.
Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL
Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder.
Castellanos FX; Elia J; Kruesi MJ; Gulotta CS; Mefford IN; Potter WZ; Ritchie GF; Rapoport JL
Psychiatry Res; 1994 Jun; 52(3):305-16. PubMed ID: 7527565
[TBL] [Abstract][Full Text] [Related]
3. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
Aman MG; Binder C; Turgay A
J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
[TBL] [Abstract][Full Text] [Related]
4. An n-of-1 trial service in clinical practice: testing the effectiveness of stimulants for attention-deficit/hyperactivity disorder.
Nikles CJ; Mitchell GK; Del Mar CB; Clavarino A; McNairn N
Pediatrics; 2006 Jun; 117(6):2040-6. PubMed ID: 16740846
[TBL] [Abstract][Full Text] [Related]
5. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
[TBL] [Abstract][Full Text] [Related]
6. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
7. ADHD in girls: clinical comparability of a research sample.
Sharp WS; Walter JM; Marsh WL; Ritchie GF; Hamburger SD; Castellanos FX
J Am Acad Child Adolesc Psychiatry; 1999 Jan; 38(1):40-7. PubMed ID: 9893415
[TBL] [Abstract][Full Text] [Related]
8. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose.
Castellanos FX; Giedd JN; Elia J; Marsh WL; Ritchie GF; Hamburger SD; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1997 May; 36(5):589-96. PubMed ID: 9136492
[TBL] [Abstract][Full Text] [Related]
9. Buspirone versus methylphenidate in the treatment of children with attention- deficit/ hyperactivity disorder: randomized double-blind study.
Mohammadi MR; Hafezi P; Galeiha A; Hajiaghaee R; Akhondzadeh S
Acta Med Iran; 2012; 50(11):723-8. PubMed ID: 23292622
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate versus dextroamphetamine in ADHD.
Efron D
J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):500. PubMed ID: 10230180
[No Abstract] [Full Text] [Related]
11. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
Stevenson RD; Wolraich ML
Pediatr Clin North Am; 1989 Oct; 36(5):1183-97. PubMed ID: 2677938
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
Faraone SV; Glatt SJ
J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
[TBL] [Abstract][Full Text] [Related]
13. [Stimulant therapy in children].
Steinhausen HC
Pharmacopsychiatria; 1982 Nov; 15(6):181-2. PubMed ID: 6130534
[No Abstract] [Full Text] [Related]
14. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.
Research Units on Pediatric Psychopharmacology Autism Network
Arch Gen Psychiatry; 2005 Nov; 62(11):1266-74. PubMed ID: 16275814
[TBL] [Abstract][Full Text] [Related]
15. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
16. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
[TBL] [Abstract][Full Text] [Related]
17. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.
Sangal RB; Sangal JM
Clin Neurophysiol; 2004 Jan; 115(1):188-93. PubMed ID: 14706487
[TBL] [Abstract][Full Text] [Related]
18. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.
Posey DJ; Aman MG; McCracken JT; Scahill L; Tierney E; Arnold LE; Vitiello B; Chuang SZ; Davies M; Ramadan Y; Witwer AN; Swiezy NB; Cronin P; Shah B; Carroll DH; Young C; Wheeler C; McDougle CJ
Biol Psychiatry; 2007 Feb; 61(4):538-44. PubMed ID: 17276750
[TBL] [Abstract][Full Text] [Related]
19. Relationships between computer-based testing and behavioral ratings in the assessment of attention and activity in a pediatric ADHD stimulant crossover trial.
Ramtvedt BE; Sundet K
Clin Neuropsychol; 2014; 28(7):1146-61. PubMed ID: 25249305
[TBL] [Abstract][Full Text] [Related]
20. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
